Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Issued (2016 - 2024)

Ultragenyx Pharmaceutical (RARE) has disclosed Shares Issued for 8 consecutive years, with $381.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Shares Issued changed N/A to $381.0 million in Q2 2024 year-over-year; TTM through Jun 2024 was $390.1 million, a N/A change, with the full-year FY2025 number at $6.0 million, down 45.45% from a year prior.
  • Shares Issued was $381.0 million for Q2 2024 at Ultragenyx Pharmaceutical, up from $2.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $381.0 million in Q2 2024 to a low of $380000.0 in Q1 2020.
  • A 4-year average of $45.3 million and a median of $9.8 million in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: tumbled 99.88% in 2020, then surged 3258.16% in 2021.
  • Ultragenyx Pharmaceutical's Shares Issued stood at $79.8 million in 2020, then crashed by 91.32% to $6.9 million in 2021, then plummeted by 71.1% to $2.0 million in 2022, then surged by 18940.48% to $381.0 million in 2024.
  • Per Business Quant, the three most recent readings for RARE's Shares Issued are $381.0 million (Q2 2024), $2.0 million (Q4 2022), and $1.1 million (Q3 2022).